Nanjing to build biomedical innovation platform

In recent years, with the Life Sciences Innovation Park, Jiangsu, Nanjing Biomedical Research Institute to establish a series of development platforms, the Nanjing Yangtze River Delta region began to build the biggest "trough." The next 3 years, the national, provincial, municipal, district four 10.0 billion joint investment of the funds will be directly contributing to guide various types of social capital invested 100 billion yuan or more, support a number of strong innovation ability and bio-pharmaceutical enterprises own intellectual property rights growing rapidly. 2013,10-Hydroxydecanoic Acid price , Nanjing will achieve super-scale bio-pharmaceutical industry, 500 billion total. In last week's 2010 International Technology Transfer Conference, Nanjing create new drugs and medical testing upload the International Cooperation Forum this information.

Forum, bio-pharmaceutical Co., Ltd. Nanjing Aide Kai Teng issued by the Ministry of Science and demonstration base of international cooperation in bio-medicine; Nanjing Pharmaceutical Industrial Group Company in Jiangsu Province was awarded the Fellow of the workstation; Nanjing Pharmaceutical Industrial Group was awarded the engineering center in Nanjing biological diagnostic reagents. In this regard, Jiangsu Province, Li Qi, deputy director of Science and Technology Department, said more than 50 billion yuan output value to achieve the goal,10-Hydroxydecanoic Acid , Nanjing, the technology needs of biomedical industry must be innovative resources overseas docking, which depends on the carrier's construction. In undertaking technology transfer from overseas, in addition to the introduction of technical understanding,10-Hydroxydecanoic Acid supplier, digestion, absorption, according to the characteristics of the Chinese market and consumer focused development and incubation, to achieve in the domestic industry.

Pharmaceutical R & D as an important base in Jiangsu, one of the bio-pharmaceutical enterprises in Nanjing in 2008, although the total number exceeded 100 years ago,CAS 1679-53-4 , of which more than 60 passed GMP certification, but in general R & D investment is still small, is still relatively Combination weak state. Nanjing International Technology Transfer Conference for this special release of the "medical testing and new drug in Nanjing Industrial Technology Innovation Alliance Proposal." Nanjing Medical testing and new drug industry technology innovation strategic alliance initiated by the six units and is still awaiting approval. After the establishment of joint venture alliances to reach dozens of plans to start operations next year.